PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 5, 2012, Pages 637-644

  Chen, Y Z ^a,b,c   Xue, J Y ^a,b   Chen, C M ^a,b   Yang, B L ^a,b   Xu, Q H ^a   Wu, F ^a   Liu, F ^a   Ye, X ^a   Meng, X ^a   Liu, G Y ^a,b   Shen, Z Z ^a,b   Shao, Z M ^a,b   Wu, J ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy response; DNA repair; Gene expression; Neoadjuvant; PPAR pathway

Indexed keywords

CARBOPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERSTITIAL COLLAGENASE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROGESTERONE RECEPTOR; RNA;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CSTA GENE; DNA REPAIR; DRUG RESPONSE; ENDOPLASMIC RETICULUM; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LPL GENE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MMP1 GENE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PLTP GENE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCD5 GENE; SIGNAL TRANSDUCTION; SORBS1 GENE; VALIDATION PROCESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84871256978     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1949-0     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942
2. Robain M, Pierga JY, Jouve M et al (2000) Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer 362:301-2312
3. Chang J, Clark GM, Allred DC et al (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97:545-553
4. Andre F, Mazouni C, Hortobagyi GN et al (2006) DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. Biochim Biophys Acta 1766:197-204
5. Chuthapisith S, Eremin JM, Eremin O (2008) Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (review). Oncol Rep 20:699-703
6. Chen XS, Nie XQ, Chen CM et al (2010) Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 21: 961-967
7. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
8. Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277
9. Hornychova H, Melichar B, Tomsova M et al (2008) Tumorinfiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 26: 1024-1031
10. Chen Y, Chen C, Yang B et al (2011) Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett 302:63-68
11. Denkert C, Loibl S, Noske A et al (2010) Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113
12. Hegi ME, Sciuscio D, Murat A (2009) Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res 15:5026-5031
13. Korde LA, Lusa L, McShane L et al (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 119:685-699
14. Wagner P, Wang B, Clark E et al (2005) Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4:1149-1152
15. Peters JM, Shah YM, Gonzalez FJ (2012) The role of peroxisome proliferator-Activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 12:181-195
16. Boitier E, Gautier JC, Roberts R (2003) Advances in understanding the regulation of apoptosis and mitosis by peroxisomeproliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol 2:3
17. Patel L, Pass I, Coxon P et al (2001) Tumor suppressor and antiinflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11:764-768
18. Mulholland DJ, Dedhar S, Coetzee GA et al (2005) Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know Endocr Rev 26:898-915
19. Zhou J, Zhang W, Liang B et al (2009) PPARgamma activation induces autophagy in breast cancer cells. Int J Biochem Cell Biol 41:2334-2342
20. Bonofiglio D, Cione E, Qi H et al (2009) Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol 175:1270-1280
21. Yuan H, Kopelovich L, Yin Y et al (2012) Drug-Targeted inhibition of peroxisome proliferator-Activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget 3:345-356
22. Rubin GL, Zhao Y, Kalus AM et al (2000) Peroxisome proliferator-Activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60:1604-1608
23. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167